Literature DB >> 28730861

Comparative Outcomes in Children and Adults With Anti- N-Methyl-D-Aspartate (anti-NMDA) Receptor Encephalitis.

Eliza Gordon-Lipkin1,2, Anusha K Yeshokumar2, Deanna Saylor2, Ana Arenivas3,4, John C Probasco2.   

Abstract

This study compared neurologic disability and adaptive function in children and adults >1 year following anti- N-methyl-d-aspartate receptor (anti-NMDAR) encephalitis diagnosis. Retrospective record review identified 12 patients with anti-NMDAR encephalitis. At last follow-up, all surviving patients had "good" modified Rankin Score (0-2). Four children, 6 adults, and their families participated in a telephone interview. Median duration since diagnosis was similar for children (2.42 years, interquartile range 2.12-3.32) and adults (3.55 years, interquartile range 2.08-5.50 years). 3/4 (75%) pediatric and 3/5 (60%) adult patients reported neuropsychiatric symptoms (fatigue, emotional lability, short-term memory deficits or concentration deficits). On the Adaptive Behavior Assessment System (ABAS-3), although overall adaptive function was intact for adults (general adaptive composite standard score: median 104.5, interquartile range 98.8-112.5), the median for children was below average (General Adaptive Composite Standard Score: median 82.0, interquartile range 79.0-89.0). Children with anti-NDMAR encephalitis may have long-term effects impacting daily life while adults regain normal function.

Entities:  

Keywords:  NMDA; adaptive; autoimmune; encephalitis; outcome

Mesh:

Year:  2017        PMID: 28730861     DOI: 10.1177/0883073817720340

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  7 in total

1.  Neuropsychological assessment as an objective tool to monitor treatment response in anti-N-methyl-D-aspartate receptor encephalitis.

Authors:  Erica Sieg; Michael Brook; Jenny Linnoila; Stephen VanHaerents
Journal:  BMJ Case Rep       Date:  2018-06-08

2.  Multimodal electrophysiological analyses reveal that reduced synaptic excitatory neurotransmission underlies seizures in a model of NMDAR antibody-mediated encephalitis.

Authors:  Sukhvir K Wright; Richard E Rosch; Max A Wilson; Manoj A Upadhya; Divya R Dhangar; Charlie Clarke-Bland; Tamara T Wahid; Sumanta Barman; Norbert Goebels; Jakob Kreye; Harald Prüss; Leslie Jacobson; Danielle S Bassett; Angela Vincent; Stuart D Greenhill; Gavin L Woodhall
Journal:  Commun Biol       Date:  2021-09-20

3.  Younger Age at Onset Is Associated With Worse Long-term Behavioral Outcomes in Anti-NMDA Receptor Encephalitis.

Authors:  Anusha Yeshokumar; Eliza Gordon-Lipkin; Ana Arenivas; Mark Rosenfeld; Kristina Patterson; Raia Blum; Brenda Banwell; Arun Venkatesan; Eric Lancaster; Jessica Panzer; John Probasco
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2022-07-06

Review 4.  Autoantibody Encephalitis: Presentation, Diagnosis, and Management.

Authors:  Eric Lancaster
Journal:  J Clin Neurol       Date:  2022-07       Impact factor: 2.566

5.  A Case of HIV Seroconversion Presenting Similarly to Anti-N-methyl-D-aspartate Receptor Encephalitis.

Authors:  Heather VanDongen-Trimmer; Kumar Sannagowdara; Binod Balakrishnan; Raquel Farias-Moeller
Journal:  Neurocrit Care       Date:  2019-10       Impact factor: 3.532

6.  Fatigue in Survivors of Autoimmune Encephalitis.

Authors:  Luisa A Diaz-Arias; Anusha Kierty Yeshokumar; Brittany Glassberg; James F Sumowski; Ava Easton; John C Probasco; Arun Venkatesan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-08-13

7.  Risk mitigation behaviors to prevent infection in the mitochondrial disease community during the COVID-19 pandemic.

Authors:  Eliza Gordon-Lipkin; Shannon Kruk; Elizabeth Thompson; Philip Yeske; Lori Martin; Michio Hirano; Bruce H Cohen; Christopher Steven Marcum; Peter J McGuire
Journal:  Mol Genet Metab Rep       Date:  2021-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.